We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MCY:NZXMercury NZ Ltd. Analysis

Data as of 2026-03-15 - not real-time

$88.96

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Mercury General (MCY) posted a 32% profit surge in Q4, with revenue up 7% and a combined ratio improving to 96.3%, underscoring strong underwriting performance. The company’s free cash flow of $2.52 B and a modest payout ratio of 13% support a sustainable dividend of 1.43%. Valuation metrics are compelling: a trailing P/E of 9.1 versus an industry average of 16.4 and an estimated upside of roughly 24% suggest the stock is significantly undervalued. ROE of 24.8% and operating margin of 16.7% highlight efficient capital use, while debt-to-equity sits at a manageable 24.3%.
Technically, the share price of $88.96 sits just below the 20‑day and 50‑day SMAs (≈$89.5) and above the 200‑day SMA, indicating a neutral to slightly bearish bias. The MACD is in bearish territory and volume trends downward, adding short‑term pressure. However, a beta of 0.64 points to lower market volatility, though the 30‑day price volatility of 38% is relatively high. Overall, the fundamentals are robust and the valuation attractive, but short‑term technical signals advise caution.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD histogram and decreasing volume
  • Price hovering just below short‑term moving averages
  • Recent earnings surprise may already be priced in

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong earnings growth and 14% revenue expansion YoY
  • Undervalued relative to peers with ~24% upside potential
  • Robust cash generation supporting dividend and debt repayment

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • High ROE and stable combined ratio indicating durable profitability
  • Low payout ratio offering dividend sustainability and growth
  • Favorable valuation metrics and solid balance sheet for long‑run upside

Key Metrics & Analysis

Financial Health

Revenue Growth14.10%
Profit Margin9.03%
P/E Ratio9.1
ROE24.80%
ROA4.82%
Debt/Equity24.32
P/B Ratio2.0
Op. Cash Flow$1.1B
Free Cash Flow$2.5B
Industry P/E16.4

Technical Analysis

TrendNeutral
RSI47.6
Support$82.42
Resistance$100.06
MA 20$89.51
MA 50$89.84
MA 200$80.81
MACDBearish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Fair Value$1,135.00
Target Price$110.00
Upside/Downside23.65%
GradeUndervalued
TypeBlend
Dividend Yield1.43%

Risk Assessment

Beta0.64
Volatility38.52%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.